Skip to main content
Top
Published in: Orphanet Journal of Rare Diseases 1/2018

Open Access 01-12-2018 | Research

Cutaneous neurofibromas in Neurofibromatosis type I: a quantitative natural history study

Authors: Ashley Cannon, Mei-Jan Chen, Peng Li, Kevin P. Boyd, Amy Theos, David T. Redden, Bruce Korf

Published in: Orphanet Journal of Rare Diseases | Issue 1/2018

Login to get access

Abstract

Background

Neurofibromatosis type 1 (NF1) is a genetic disorder characterized by a predisposition to develop multiple benign tumors. A major feature of NF1 is the development of localized cutaneous neurofibromas. Cutaneous neurofibromas manifest in > 99% of adults with NF1 and are responsible for major negative effects on quality of life. Previous reports have correlated increased burden of cutaneous neurofibromas with age and pregnancy, but longitudinal data are not available to establish a quantitative natural history of these lesions. The purpose of this study is to conduct a prospective natural history study of 22 adults with NF1 over an 8-year period to quantify cutaneous neurofibroma number and size.

Results

The average monthly increase in volume for cutaneous neurofibromas was 0.37 mm3 in the back region (95% CI (0.23, 0.51), p < 0.0001), 0.28 mm3 in the abdominal region (95% CI (0.16, 0.41), p < 0.0001), and 0.21 mm3 in the arm/leg region (95% CI (0.08, 0.34), p = 0.0022). The number of cutaneous neurofibromas significantly increased in the back (slope = 0.032, p = 0.011) and abdominal (slope = 0.018, p = 0.026) regions, while the leg/arm regions retained a positive trend (slope = 0.004, p = 0.055).

Conclusions

The number and volume of cutaneous neurofibromas significantly increased over an 8-year timespan; however, the rate of increase is variable by individual and body region. These findings may provide insight into cutaneous neurofibroma development and benefit researchers considering clinical trials targeting cutaneous neurofibromas.
Appendix
Available only for authorised users
Literature
1.
go back to reference Huson SM, Harper PS, Compston DA. Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain. 1988;111(Pt 6):1355–81.CrossRefPubMed Huson SM, Harper PS, Compston DA. Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain. 1988;111(Pt 6):1355–81.CrossRefPubMed
2.
3.
go back to reference Duong TA, Bastuji-Garin S, Valeyrie-Allanore L, Sbidian E, Ferkal S, Wolkenstein P. Evolving pattern with age of cutaneous signs in neurofibromatosis type 1: a cross-sectional study of 728 patients. Dermatology. 2011;222:269–73.CrossRefPubMed Duong TA, Bastuji-Garin S, Valeyrie-Allanore L, Sbidian E, Ferkal S, Wolkenstein P. Evolving pattern with age of cutaneous signs in neurofibromatosis type 1: a cross-sectional study of 728 patients. Dermatology. 2011;222:269–73.CrossRefPubMed
4.
go back to reference Wolkenstein P, Zeller J, Revuz J, Ecosse E, Leplege A. Quality-of-life impairment in neurofibromatosis type 1: a cross-sectional study of 128 cases. Arch Dermatol. 2001;137:1421–5.CrossRefPubMed Wolkenstein P, Zeller J, Revuz J, Ecosse E, Leplege A. Quality-of-life impairment in neurofibromatosis type 1: a cross-sectional study of 128 cases. Arch Dermatol. 2001;137:1421–5.CrossRefPubMed
5.
go back to reference Kodra Y, Giustini S, Divona L, Porciello R, Calvieri S, Wolkenstein P, et al. Health-related quality of life in patients with neurofibromatosis type 1. A survey of 129 Italian patients. Dermatology. 2009;218:215–20.CrossRefPubMed Kodra Y, Giustini S, Divona L, Porciello R, Calvieri S, Wolkenstein P, et al. Health-related quality of life in patients with neurofibromatosis type 1. A survey of 129 Italian patients. Dermatology. 2009;218:215–20.CrossRefPubMed
6.
go back to reference Page PZ, Page GP, Ecosse E, Korf BR, Leplege A, Wolkenstein P. Impact of neurofibromatosis 1 on quality of life: a cross-sectional study of 176 American cases. Am J Med Genet A. 2006;140:1893–8.CrossRefPubMed Page PZ, Page GP, Ecosse E, Korf BR, Leplege A, Wolkenstein P. Impact of neurofibromatosis 1 on quality of life: a cross-sectional study of 176 American cases. Am J Med Genet A. 2006;140:1893–8.CrossRefPubMed
7.
go back to reference Becker DW Jr. Use of the carbon dioxide laser in treating multiple cutaneous neurofibromas. Ann Plast Surg. 1991;26:582–6.CrossRefPubMed Becker DW Jr. Use of the carbon dioxide laser in treating multiple cutaneous neurofibromas. Ann Plast Surg. 1991;26:582–6.CrossRefPubMed
8.
go back to reference Bromley GS, Sherman JE, Goulian D Jr. Neurofibromatosis-distribution of lesions and surgical treatment. Ann Plast Surg. 1982;8:272–6.CrossRefPubMed Bromley GS, Sherman JE, Goulian D Jr. Neurofibromatosis-distribution of lesions and surgical treatment. Ann Plast Surg. 1982;8:272–6.CrossRefPubMed
9.
go back to reference Elwakil TF, Samy NA, Elbasiouny MS. Non-excision treatment of multiple cutaneous neurofibromas by laser photocoagulation. Lasers Med Sci. 2008;23:301–6.CrossRefPubMed Elwakil TF, Samy NA, Elbasiouny MS. Non-excision treatment of multiple cutaneous neurofibromas by laser photocoagulation. Lasers Med Sci. 2008;23:301–6.CrossRefPubMed
10.
go back to reference Kim HJ, Lee KG, Yi SM, Kim JH, Kim IH. Successful treatment of multiple cutaneous neurofibromas using a combination of shave excision and laser photothermocoagulation with a 1,444-nm neodymium-doped yttrium aluminum garnet laser. Dermatol Surg. 2012;38:960–3.CrossRefPubMed Kim HJ, Lee KG, Yi SM, Kim JH, Kim IH. Successful treatment of multiple cutaneous neurofibromas using a combination of shave excision and laser photothermocoagulation with a 1,444-nm neodymium-doped yttrium aluminum garnet laser. Dermatol Surg. 2012;38:960–3.CrossRefPubMed
11.
go back to reference Kriechbaumer LK, Susani M, Kircher SG, Happak W. Vaporization of cutaneous neurofibromas with an erbium: yttrium-aluminum-garnet laser: a comparative histologic evaluation. Plast Reconstr Surg. 2012;129:602e–4e.CrossRefPubMed Kriechbaumer LK, Susani M, Kircher SG, Happak W. Vaporization of cutaneous neurofibromas with an erbium: yttrium-aluminum-garnet laser: a comparative histologic evaluation. Plast Reconstr Surg. 2012;129:602e–4e.CrossRefPubMed
12.
go back to reference Meni C, Sbidian E, Moreno JC, Lafaye S, Buffard V, Goldzal S, et al. Treatment of neurofibromas with a carbon dioxide laser: a retrospective cross-sectional study of 106 patients. Dermatology. 2015;230:263–8.CrossRefPubMed Meni C, Sbidian E, Moreno JC, Lafaye S, Buffard V, Goldzal S, et al. Treatment of neurofibromas with a carbon dioxide laser: a retrospective cross-sectional study of 106 patients. Dermatology. 2015;230:263–8.CrossRefPubMed
13.
go back to reference Moreno JC, Mathoret C, Lantieri L, Zeller J, Revuz J, Wolkenstein P. Carbon dioxide laser for removal of multiple cutaneous neurofibromas. Br J Dermatol. 2001;144:1096–8.CrossRefPubMed Moreno JC, Mathoret C, Lantieri L, Zeller J, Revuz J, Wolkenstein P. Carbon dioxide laser for removal of multiple cutaneous neurofibromas. Br J Dermatol. 2001;144:1096–8.CrossRefPubMed
14.
go back to reference Roenigk RK, Ratz JL. CO2 laser treatment of cutaneous neurofibromas. J Dermatol Surg Oncol. 1987;13:187–90.CrossRefPubMed Roenigk RK, Ratz JL. CO2 laser treatment of cutaneous neurofibromas. J Dermatol Surg Oncol. 1987;13:187–90.CrossRefPubMed
15.
go back to reference Cunha KS, Rozza-de-Menezes RE, Andrade RM, Theos A, Luiz RR, Korf B, et al. Validity and interexaminer reliability of a new method to quantify skin neurofibromas of neurofibromatosis 1 using paper frames. Orphanet J Rare Dis. 2014;9:202.CrossRefPubMedPubMedCentral Cunha KS, Rozza-de-Menezes RE, Andrade RM, Theos A, Luiz RR, Korf B, et al. Validity and interexaminer reliability of a new method to quantify skin neurofibromas of neurofibromatosis 1 using paper frames. Orphanet J Rare Dis. 2014;9:202.CrossRefPubMedPubMedCentral
16.
go back to reference Morgan CJ, Aban I. Methods for evaluating the agreement between diagnostic tests. J Nucl Cardiol. 2016;23:511–3.CrossRefPubMed Morgan CJ, Aban I. Methods for evaluating the agreement between diagnostic tests. J Nucl Cardiol. 2016;23:511–3.CrossRefPubMed
17.
go back to reference Thomas L, Kluwe L, Chuzhanova N, Mautner V, Upadhyaya M. Analysis of NF1 somatic mutations in cutaneous neurofibromas from patients with high tumor burden. Neurogenetics. 2010;11:391–400.CrossRefPubMed Thomas L, Kluwe L, Chuzhanova N, Mautner V, Upadhyaya M. Analysis of NF1 somatic mutations in cutaneous neurofibromas from patients with high tumor burden. Neurogenetics. 2010;11:391–400.CrossRefPubMed
19.
go back to reference Laycock-van Spyk S, Thomas N, Cooper DN, Upadhyaya M. Neurofibromatosis type 1-associated tumours: their somatic mutational spectrum and pathogenesis. Hum Genomics. 2011;5:623–90.CrossRefPubMed Laycock-van Spyk S, Thomas N, Cooper DN, Upadhyaya M. Neurofibromatosis type 1-associated tumours: their somatic mutational spectrum and pathogenesis. Hum Genomics. 2011;5:623–90.CrossRefPubMed
20.
go back to reference Dombi E, Baldwin A, Marcus LJ, Fisher MJ, Weiss B, Kim A, et al. Activity of Selumetinib in Neurofibromatosis type 1-related Plexiform Neurofibromas. N Engl J Med. 2016;375:2550–60.CrossRefPubMedPubMedCentral Dombi E, Baldwin A, Marcus LJ, Fisher MJ, Weiss B, Kim A, et al. Activity of Selumetinib in Neurofibromatosis type 1-related Plexiform Neurofibromas. N Engl J Med. 2016;375:2550–60.CrossRefPubMedPubMedCentral
21.
go back to reference Gutmann DH, Blakeley JO, Korf BR, Packer RJ. Optimizing biologically targeted clinical trials for neurofibromatosis. Expert Opin Investig Drugs. 2013;22:443–62.CrossRefPubMedPubMedCentral Gutmann DH, Blakeley JO, Korf BR, Packer RJ. Optimizing biologically targeted clinical trials for neurofibromatosis. Expert Opin Investig Drugs. 2013;22:443–62.CrossRefPubMedPubMedCentral
Metadata
Title
Cutaneous neurofibromas in Neurofibromatosis type I: a quantitative natural history study
Authors
Ashley Cannon
Mei-Jan Chen
Peng Li
Kevin P. Boyd
Amy Theos
David T. Redden
Bruce Korf
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2018
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-018-0772-z

Other articles of this Issue 1/2018

Orphanet Journal of Rare Diseases 1/2018 Go to the issue